Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Gyros Immunoassay Platform Selected by BioAgilytix Labs to Support Bioanalysis Services

Published: Tuesday, November 12, 2013
Last Updated: Tuesday, November 12, 2013
Bookmark and Share
Gyros AB announced that BioAgilytix Labs has invested in two Gyrolab™ xP workstations to support its bioanalysis services.

Dr. Afshin Safavi, Founder and Chief Scientific Officer at BioAgilytix Labs, said: “As a trusted partner to six of the top ten global pharmaceutical and biotech companies, it is vital that we broaden our technology offering and continue to deliver the highest quality bioanalysis possible. In the hands of our highly experienced scientists, the Gyros platform will allow BioAgilytix to continue to provide the quality data our customers have grown to expect, while also meeting growing capacity demands. Moreover, the nanoliter scale of the platform enables us to generate such data from small volumes of precious sample, maximizing the number of assays that can be performed.”
“Major biopharmaceutical companies are increasingly desiring that immunoassay testing be developed and completed using Gyrolab xP workstations due to its high precision, low sample volumes, and ease with which assays can be transferred,” commented Dan Calvo, CEO at Gyros. “We are delighted that BioAgilytix has adopted the Gyros platform and are confident it will enable them to continue to provide their customers with high quality bioanalysis.”
Gyros platform comprises Gyrolab workstation, control and evaluation software, and the unique microfluidic Gyrolab Bioaffy CDs in which immunoassay steps are integrated and run at nanoliter scale.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Gyros and Tekon Biotech Sign Distribution Agreement
Tekon will distribute Gyros’ immunoassay platform in China, Taiwan & Hong Kong.
Tuesday, April 01, 2014
Dan Calvo Appointed CEO of Gyros AB
Erik Walldén steps down as chief executive officer and president.
Thursday, October 24, 2013
Gyros AB Appoints Dr. Claus Braestrup to the Board of Directors
Dr. Braestrup is a member of the Board of Directors of Bavarian Nordic A/S, Chairman of the Board of Probiodrug AG and a member of the Boards of Santaris Pharma A/S and Evolva Holding SA.
Monday, January 28, 2013
Gyros AB Appoints Dr Henrik Björkman as CTO and VP Technical Affairs
Dr Henrik Björkman will lead the R&D and product supply teams.
Monday, January 21, 2013
Gyros AB Quality Management System Receives ISO 9001:2008 Certification
Certification reassures customers that they receive consistently high standard of products and services.
Tuesday, December 18, 2012
Gyros Expands Asian Distribution to Singapore
Nanoliter-scale immunoassay platform now available to biopharmaceutical companies in Singapore region.
Thursday, June 07, 2012
Gyros and GE Healthcare Life Sciences Expand Asian Distribution Relationship
Gyros AB announces that GE Healthcare Life Sciences has become sole distributor for the company’s nanoliter-scale immunoassay platform in China, Taiwan and Hong Kong.
Friday, August 26, 2011
Gyros and GE Healthcare Life Sciences Sign Distribution Agreement for Japan
Brings the Gyros nanoliter-scale immunoassay platform to biopharmaceutical and vaccine manufacturers in Japan.
Thursday, July 14, 2011
Gyros and GE Healthcare Life Sciences Sign Distribution Agreement
Gyros AB announces that GE Healthcare Life Sciences has become the sole distributor for the company’s nanoliter-scale immunoassay platform in Japan.
Tuesday, July 12, 2011
Scientific News
Lung Repair and Regeneration Gene Discovered
New role for hedgehog gene offers better understanding of lung disease.
How Cell Growth Triggers Cell Division
Researchers in Jan Skotheim's lab have discovered a previously unknown mechanism that controls how large cells grow, an insight that could one day provide insight into attacking diseases such as cancer.
Microbe Sleuth
Tanja Bosak examines how life and the Earth evolved in tandem during their early history together.
3 Ways Viruses Have Changed Science for the Better
Viruses are really good at what they do, and we’ve been able to harness their skills to learn about – and potentially improve – human health in several ways.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Self-Propelled Powder to Stop Bleeding
UBC researchers have created the first self-propelled particles capable of delivering coagulants against the flow of blood to treat severe bleeding, a potentially huge advancement in trauma care.
Five New Genetic Variants Linked to Brain Cancer Identified
The biggest ever study of DNA from people with glioma – the most common form of brain cancer – has discovered five new genetic variants associated with the disease.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos